Immunoexpression of inhibitors of apoptosis proteins and their antagonist SMAC/DIABLO in colorectal carcinoma: Correlation with apoptotic index, cellular proliferation and prognosis

Oncology Reports

Volumn 22, Issue 2, 2009, Pages 295-303

  Lima, Flávio De Oliveira ^a   Costa, Henrique De Oliveira ^a   Barrezueta, Luis Fernando Mesias ^a   Oshima, Celina Tizuko Fujiyama ^a   Silva Jr , José Antonio ^b   Gomes, Thiago Simão ^a   Pinheiro Jr , Nathanael ^a   Neto, Ricardo Artigiani ^a   Franco, Marcello ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSIDADE NOVE DE JULHO   (Brazil)

Author keywords

Apoptosis; Colorectal carcinoma; IAPs; Immunohistochemistry; Prognosis; SMAC

Indexed keywords

CASPASE 3; CYTOKERATIN 18; INHIBITOR OF APOPTOSIS PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 1; INHIBITOR OF APOPTOSIS PROTEIN 2; PROTEIN ANTIBODY; PROTEIN P53; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SURVIVIN; X LINKED INHIBITOR OF APOPTOSIS;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CANCER TISSUE; CELL PROLIFERATION; COLON CARCINOGENESIS; COLON MUCOSA; COLORECTAL CARCINOMA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECTUM MUCOSA; SCORING SYSTEM; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CELL PROLIFERATION; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; MITOCHONDRIAL PROTEINS; PROGNOSIS; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 68349102924     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000437     Document Type: Article

References (52)

1. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM and Bos JL: Genetic alterations during colorectal-tumor development. N Engl J Med 319: 525-532, 1988.
2. Fearon ER and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61: 759-767, 1990.
3. Arnold CN, Goel A, Blum HE and Boland CR: Molecular pathogenesis of colorectal cancer: implications for molecular diagnosis. Cancer 104: 2035-2047, 2005.
4. Conlin A, Smith G, Carey FA, Wolf CR and Steele RJ: The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut 54: 1283-1286, 2005.
5. Barrier A, Boelle PY, Roser F, Gregg J, Tse C, Brault D, Lacaine F, Houry S, Huguier M, Franc B, Flahault A, Lemoine A and Dudoit S: Stage II colon cancer prognosis prediction by tumor gene expression profiling. J Clin Oncol 24: 4685-4691, 2006.
6. Caldwell GM, Jones CE, Taniere P, Warrack R, Soon Y, Matthews GM and Morton DG: The Wnt antagonist sFRP1 is downregulated in premalignant large bowel adenomas. Br J Cancer 94: 922-927, 2006.
7. Lyall MS, Dundas SR, Curran S and Murray GI: Profiling markers of prognosis in colorectal cancer. Clin Cancer Res 12: 1184-1191, 2006.
8. Penegar S, Wood W, Lubbe S, Chandler I, Broderick P, Papaemmanuil E, Sellic G, Gray R, Peto J and Houlston R: National study of colorectal cancer genetics. Br J Cancer 97: 1305-1309, 2007.
9. Hengartner MO: The biochemistry of apoptosis. Nature 407: 770-776, 2000.
10. Kumar S: Caspase function in programmed cell death. Cell Death Differ 14: 32-43, 2007.
11. Liston P, Fong WG and Korneluk RG: The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene 22: 8568-8580, 2003.
12. Callus BA and Vaux D: Caspase inhibitors: viral, cellular and chemical. Cell Death Differ 14: 73-78, 2007.
13. Deveraux QL and Reed JC: IAP family proteins - suppressors of apoptosis. Genes Dev 13: 239-252, 1999.
14. Hay BA: Understanding IAP function and regulation: a view from Drosophila. Cell Death Differ 7: 1045-1056, 2000.
15. Bruno T, Iezzi S, De Nicola F, Di Padova M, Desantis A, Scarsella M, Di Certo MG, Leonetti C, Floridi A, Passananti C and Fanciulli M: Che-1 activates XIAP expression in response to DNA damage. Cell Death Differ 15: 515-520, 2008.
16. Rigaud S, Fondaneche MC, Lambert N, Pasquier B, Mateo V, Soulas P, Galicier L, Le Deist F, Rieux-Lacaut F, Revy P, Fischer A, De Saint Basile G and Latour S: XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature 444: 110-114, 2006.
17. Kim EH, Kim HS, Kim SU, Noh EJ, Lee JS and Choi KS: Sodium butyrate sensitizes human glioma cells to TRAIL-mediated apoptosis through inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP. Oncogene 24: 6877-6889, 2005.
18. Vogler M, Durr K, Jovanovic M, Debatin KM and Fulda S: Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells. Oncogene 26: 248-257, 2007.
19. Schimmer AD, Dalili S, Batey RA and Riedl SJ: Targeting XIAP for the treatment of malignancy. Cell Death Differ 13: 179-188, 2006.
20. Bilim V, Yuuki K, Itoi T, Muto A, Kato T, Nagaoka A, Motoyama T and Tomita Y: Double inhibition of XIAP and Bcl-2 axis is beneficial for retrieving sensitivity of renal cell cancer to apoptosis. Br J Cancer 98: 941-949, 2008.
21. Endo T, Abe S, Seidlar HB, Nagaoka S, Takemura T, Utsuyama M, Kitagawa M and Hirokawa K: Expression of IAP family proteins in colon cancers from patients with different age groups. Cancer Immunol Immunother 53: 770-776, 2004.
22. Pinho MDSL, Ghislandi LR, Fronza H Jr, Wengerkiewicz A, Pereira Filho A, Ferreira LC, Kleinubing H Jr and Ferreira LE: Valor prognóstico da expressão da proteína survivina em pacientes submetidos a tratamento cirusgico no cancer coloretal. Rev Bras Coloproct 25: 121-127, 2005.
23. Rodriguez JA, Span SW, Ferreira CG, Kruyt FA and Giaccone G: CRM1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein Survivin. Exp Cell Res 275: 44-53, 2002.
24. Vegran F, Boidot R, Oudin C, Defrain C, Rebucci M and Lizard-Nacol S: Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer. Oncogene 26: 290-297, 2007.
25. Barnes N, Haywood P, Flint P, Knox WF and Bundred NJ: Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence. Br J Cancer 94: 253-258, 2006.
26. Altieri DC: Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22: 8581-8589, 2003.
27. Stucki JW and Simon HU: Mathematical modeling of the regulation of caspase-3 activation and degradation. J Theor Biol 234: 123-131, 2005.
28. Verhagen AM, Kratina TK, Hawkins CJ, Silke J, Ekert PG and Vaux DL: Identification of mammalian mitochondrial proteins that interact with IAPs via N-terminal IAP binding motifs. Cell Death Differ 14: 348-357, 2007.
29. Wang Q, Wang X and Evers BM: Induction of cIAP-2 in human colon cancer cells through PKC delta/NF-kappa B. J Biol Chem 278: 51091-51099, 2003.
30. Nishihara H, Kizaka-Kondoh S, Insel PA and Eckmann L: Inhibition of apoptosis in normal and transformed intestinal epithelial cells by cAMP through induction of inhibitor of apoptosis protein (IAP)-2. Proc Natl Acad Sci USA 100: 8921-8926, 2003.
31. Liu Z, Li H, Wu X, Yoo BH, Yan SR, Stadnyk AW, Sasazuki T, Shirasawa S, La Casse EC, Korneluk RJ and Rosen KW: Detachment-induced upregulation of XIAP and cIAP2 delays anoikis of intestinal epithelial cells. Oncogene 25: 7680-7690, 2006.
32. Song Z, Yao X and Wu M: Direct interaction between survivin and Smac/ DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem 278: 23130-23140, 2003.
33. Ceballos-Cancino G, Espinosa M, Maldonado V and Melendez-Zajgla J: Regulation of mitochondrial Smac/DIABLO-selective release by survivin. Oncogene 26: 7569-7575, 2007.
34. McNeish IA, Lopes R, Bell SJ, McKay TR, Fernandez M, Lockley M, Wheatley SP and Lemoine NR: Survivin interacts with Smac/DIABLO in ovarian carcinoma cells but is redundant in Smac-mediated apoptosis. Exp Cell Res 302: 69-82, 2005.
35. Rehm M, Huber HJ, Dussmann H and Prehn JH: Systems analysis of effector caspase activation and its control by X-linked inhibitor of apoptosis protein. EMBO J 25: 4338-4349, 2006.
36. Yan H, Thomas J, Liu T, Raj D, London N, Tandeski T, Leachman ST, Lee RM and Grossman D: Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable Survivin antagonist. Oncogene 25: 6968-6974, 2006.
37. Wang Z, Cuddy M, Samuel T, Welsh K, Schimmer A, Hanaii F, Hougthen R, Pinilla C and Reed JC: Cellular, biochemical, and genetic analysis of mechanism of small molecule IAP inhibitors. J Biol Chem 279: 48168-48176, 2004.
38. Hamilton SR, Rubio CA and Volgelstein B: Tumors of the Digestive System. 1st edition. IARC Press, Lyon, 2000.
39. Ogino S, Brahmandam M, Cantor M, Namgyal C, Kawasaki T, Kirkner G, Meyerhardt JA, Loda M and Fuchs CS: Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol 19: 59-68, 2006.
40. Holubec H, Payne CM, Bernstein H, Dvorakova K, Bernstein C, Waltmire CN, Warnerke JA and Garewal H: Assessment of apoptosis by immunohistochemical markers compared to cellular morphology in ex vivo-stressed colonic mucosa. J Histochem Cytochem 53: 229-325, 2005.
41. Kim EH, Kim SU and Choi KS: Rottlerin sensitizes glioma cells to TRAIL-induced apoptosis by inhibition of Cdc2 and the subsequent down-regulation of survivin and XIAP. Oncogene 24: 838-849, 2005.
42. Ponnelle T, Chapusot C, Martin L, Bonithon-Kopp C, Bouvier AM, Plenchette S, Rageot D, Faivre J, Solary E and Piard F: Subcellular expression of c-IAP1 and c-IAP2 in colorectal cancers: relationships with clinicopathological features and prognosis. Pathol Res Pract 199: 723-731, 2003.
43. Ponnelle T, Chapusot C, Martin L, Bouvier AM, Plenchette S, Faivre J, Solary E and Piard F: Cellular localisation of survivin: impact on the prognosis in colorectal cancer. J Cancer Res Clin Oncol 131: 504-510, 2005.
44. Rodel F, Hoffmann J, Grabenbauer GG, Papadopoulos T, Weiss C, Gunther K, Schick C, Sauer R and Rodel C: High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection. Strahlenther Onkol 178: 426-435, 2002.
45. Wu M, Yuan S, Szporn AH, Gan L, Shtilbans V and Burstein DE: Immunocytochemical detection of XIAP in body cavity effusions and washes. Mod Pathol 18: 1618-1622, 2005.
46. Emanuel PO, Phelps RG, Mudgil A, Shafir M and Burstein DE: Immunohistochemical detection of XIAP in melanoma. J Cutan Pathol 35: 292-297, 2008.
47. Sarela AI, Macadam RC, Farmery SM, Markham AF and Guillou PJ: Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 46: 645-650, 2000.
48. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T and Tanigawa N: Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 58: 5071-5074, 1998.
49. Kawasaki H, Toyoda M, Shinohara H, Okuda J, Watanabe I, Yamamoto T, Tanaka K, Tenjo T and Tanigawa N: Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer 91: 2026-2032, 2001.
50. Abd El-Hameed A: Survivin expression in colorectal adenocarcinoma using tissue microarray. J Egypt Natl Canc Inst 17: 42-50, 2005.
51. Jiang ZM, Yao HR, Zhan J, Xie DR and Li HG: Expression and significance of survivin in colon cancer. Ai Zheng 23: 1414-1417, 2004.
52. Khor TO, Gul YA, Ithnin H and Seow HF: A comparative study of the expression of Wnt-1, WISP-1, survivin and cyclin-D1 in colorectal carcinoma. Int J Colorectal Dis 21: 291-300, 2006.